France· FR:60205159
BENLYSTA 200 mg, solution injectable en stylo prérempli
A medicinal product containing bélimumab, registered in France by GLAXOSMITHKLINE (IRELAND), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- BÉLIMUMAB
- Manufacturer
- GLAXOSMITHKLINE (IRELAND)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip1334009301268991 stylo prérempli en verre de 1 mL avec aiguille sécuriséeEUR 215.1
- cip1334009301269054 stylos composés de 4 seringues préremplies en verre de 1 ml avec aiguilles sécuriséesEUR 835.3
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bélimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandBenlysta 200 mg solution for injection in pre-filled penGlaxoSmithKline (Ireland) Limited
- NetherlandsBenlysta 200 mg oplossing voor injectie in voorgevulde penGlaxoSmithKline (Ireland) Ltd.
- FinlandBenlystaGlaxoSmithKline (Ireland) Limited
- CzechiaBENLYSTAGlaxoSmithKline (Ireland) Limited, Dublin
- United StatesBENLYSTAGlaxoSmithKline LLC
- BelgiumBenlysta 120 mgGlaxoSmithKline
- SwitzerlandBenlysta
- IcelandBenlystaGlaxoSmithKline (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Benlysta
- Liechtenstein · Benlysta
- Norway · Benlysta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ceb39e40-adeb-4ed0-b30b-68ebb499f329 GET /v1/drugs/ceb39e40-adeb-4ed0-b30b-68ebb499f329?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60205159",
"date_amm": "2017-11-10",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/11/700",
"substance": "BÉLIMUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about bélimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.